Balasa Dinverno & Foltz’s Bio-Rad Laboratories Class A BIO Stock Holding History

Balasa Dinverno & Foltz’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-547	Closed	-$271K	–	339
2022 Q2	$271K	Sell	547 -401	-42%	-$209K	0.02%	284
2022 Q1	$534K	Sell	948 -326	-26%	-$197K	0.04%	188
2021 Q4	$963K	Buy	1,274 +230	+22%	+$172K	0.06%	133
2021 Q3	$779K	Buy	1,044 +48	+5%	+$36K	0.05%	143
2021 Q2	$642K	Sell	996 -69	-6%	-$42K	0.05%	161
2021 Q1	$608K	Buy	1,065 +38	+4%	+$22.5K	0.05%	160
2020 Q4	$599K	Buy	1,027 +158	+18%	+$90K	0.05%	151
2020 Q3	$448K	Buy	869 +205	+31%	+$104K	0.04%	162
2020 Q2	$300K	Buy	+664	New	+$293K	0.03%	174

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balasa Dinverno & Foltz's BIO Position: Q3 2022 in Review

Balasa Dinverno & Foltz sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 547 shares — an estimated $271K sold.

Balasa Dinverno & Foltz first reported a position in BIO in Q2 2020 and held it in 9 quarters. The position peaked at $963K in Q4 2021. 486 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

Balasa Dinverno & Foltz reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
Balasa Dinverno & Foltz sold 547 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $271K.
Balasa Dinverno & Foltz first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 9 quarters.
Balasa Dinverno & Foltz's Bio-Rad Laboratories Class A position peaked at $963K in Q4 2021.
486 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.